DrugBiological
Retifanlimab clinical trials
Also written MGA012, INCMGA00012 and Zynyz.
- studies test it
- 49
- open now
- 15
- in phase 3
- 6
- first study started
- 2015
Keep track of what changes. Save the retifanlimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
48 studies that test it; most in 2020 (10); 1 more planned to start later
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 4 |
| 2019 | 5 |
| 2020 | 10 |
| 2021 | 3 |
| 2022 | 5 |
| 2023 | 6 |
| 2024 | 4 |
| 2025 | 3 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 19
- Phase 2
- 32
- Phase 3
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 18 · Other 31
Incyte Corporation (9) · MacroGenics (6) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (4) · University of Washington (2) · BriaCell Therapeutics Corporation (2) · Anwaar Saeed (2) · M.D. Anderson Cancer Center (2) · Institut Bergonié (1)
Often tested with
Tested in the same studies.
Tuparstobart (4) · Verzistobart (4) · Tebotelimab (3) · Pembrolizumab (2) · Cisplatin (2) · Paclitaxel (2) · SV-BR-1-GM (2) · Ruxolitinib (2)
Studies
Open first, then newest update. How each study uses retifanlimab is read from its arms, and is right about nine times in ten.
Testing it · 49
- ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1Not yet recruitingPhase 1/2University of Wisconsin, MadisonNCT07472322Written as ASTX727 + retifanlimab
- 9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)RecruitingPhase 1Anwaar SaeedNCT06896188Written as Retifanlimab
- A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered GliomaRecruitingEarly Phase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06610682Written as Retifanlimab
- Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.RecruitingPhase 3BriaCell Therapeutics CorporationNCT06072612Written as Retifanlimab
- Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)RecruitingPhase 2Scott R. Plotkin, MD, PhDNCT04374305Written as Retifanlimab
- A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)RecruitingPhase 2Lund University HospitalNCT06389799Written as Retifanlimab
- Trial of Retifanlimab With Trastuzumab and Pertuzumab Combination in HER2-Addicted Breast CancerNot yet recruitingPhase 2Polly A. Niravath, MDNCT07772245Written as Retifanlimab
- Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PCNot yet recruitingPhase 2Massachusetts General HospitalNCT07765836Written as Retifanlimab
- ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal CancerRecruitingPhase 2Jennifer DorthNCT07425054Written as Retifanlimab
- Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid TumorsRecruitingPhase 1/2OHSU Knight Cancer InstituteNCT06320405Written as Retifanlimab
- NIMBLE-CRC: NeoImmunoModulation Before Leveraging Excision in Colorectal Rectal CancerNot yet recruitingPhase 2Northwell HealthNCT07677579Written as Retifanlimab
- Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade GliomasRecruitingPhase 1/2Mayo ClinicNCT07468136Written as Retifanlimab
- Retifanlimab and Ruxolitinib In Solid MalignanciesRecruitingPhase 1/2University of California, San DiegoNCT07219576Written as Retifanlimab
- Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With GlioblastomaRecruitingPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT05083754Written as Retifanlimab
- Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent GlioblastomaRecruitingPhase 2Academic and Community Cancer Research UnitedNCT06160206Written as Retifanlimab
- Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO)Active, not recruitingPhase 2Institut BergoniéNCT04968106Written as INCMGA00012
- A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)SuspendedPhase 1M.D. Anderson Cancer CenterNCT06959537Written as Retifanlimab
- Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).CompletedPhase 3Incyte CorporationNCT04472429Written as retifanlimab
- Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin MalignancyActive, not recruitingPhase 1University of Southern CaliforniaNCT04387084Written as Retifanlimab
- Palbociclib and INCMGA00012 in People With Advanced LiposarcomaActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT04438824Written as INCMGA00012
See all 49 studies that test retifanlimab →
Given in every arm · 19 — retifanlimab is usual care beside what is tested
- Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)RecruitingPhase 1/2National Cancer Institute (NCI)NCT06149481Written as Retifanlimab
- Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue SarcomaRecruitingPhase 1/2Memorial Sloan Kettering Cancer CenterNCT04577014Written as Retifanlimab
- A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D MutationRecruitingPhase 1Incyte CorporationNCT06179160Written as Retifanlimab
- All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant GliomaRecruitingPhase 2Stephen Bagley, MD, MSCENCT05345002Written as Retifanlimab
- Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)RecruitingPhase 2Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)NCT05177133Written as Retifanlimab
- Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedPhase 2Incyte Biosciences International SàrlNCT05287113Written as Retifanlimab
- Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCCActive, not recruitingPhase 1Providence Health & ServicesNCT04470024Written as INCMGA00012
- A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid TumorsTerminatedPhase 1/2Incyte CorporationNCT06873789Written as Retifanlimab
- Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent GlioblastomaActive, not recruitingPhase 2University of PennsylvaniaNCT04225039Written as INCMGA00012
- Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )TerminatedPhase 1/2Ariceum Therapeutics GmbHNCT06939036Written as Retifanlimab
- Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent GliomasCompletedPhase 2Washington University School of MedicineNCT03532295Written as Retifanlimab
- A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced MalignanciesTerminatedPhase 1Incyte CorporationNCT03522142Written as INCMGA00012
- Study of INCA 0186 in Subjects With Advanced Solid TumorsTerminatedPhase 1Incyte CorporationNCT04989387Written as Retifanlimab
- INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid TumorsCompletedPhase 1Incyte CorporationNCT04580485Written as INCMGA00012
- The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.TerminatedPhase 2Incyte CorporationNCT04949191Written as Retifanlimab
- INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaWithdrawnPhase 2Incyte Biosciences International SàrlNCT05359692Written as retifanlimab
- INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid TumorsCompletedPhase 1Incyte CorporationNCT03589651Written as Retifanlimab
- Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)TerminatedPhase 1/2Incyte CorporationNCT02393248Written as Retifanlimab
- INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)WithdrawnPhase 1Incyte CorporationNCT03920839Written as Retifanlimab
Codes
What other systems call retifanlimab · ClinicalTrials.gg INT002166
- MeSH (NLM) C000731936retifanlimabOne source NLM
- UNII (FDA) 2Y3T5IF01ZRETIFANLIMABConfirmed FDA, NLM, Wikidata
- Wikidata Q117349369retifanlimabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C142168RetifanlimabOne source FDA
- DrugBank DB15766One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731936 | retifanlimab | One source NLM |
| UNII (FDA) | 2Y3T5IF01Z | RETIFANLIMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q117349369 | retifanlimab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C142168 | Retifanlimab | One source FDA |
| DrugBank | DB15766 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.